Psilocin glucuronide in whole blood: a stable and useful biomarker of psilocybin intake
Bergh Marianne Skov-Skov, Bogen Inger Lise, Vevelstad Merete, Øiestad Åse Marit Leere
Publication record · Explore literaturePublic tracker catalogue and stored structured reference metadata. External references may have identifiers only. No live external citation lookup is performed.
References — this paper cites (33)
- Clinical Pharmacokinetics of Psilocin After Psilocybin Administration: A Systematic Review and Post-Hoc Analysis 2025-01-01 · Expand citations
- National and regional trends in seizures of shrooms (psilocybin) in the United States, 2017-2022. 2024-05-01 · Expand citations
- In vitro and in vivo metabolism of psilocybin’s active metabolite psilocin 2024-04-29 · Expand citations
- Quantification of psilocin in human whole blood using liquid chromatography-tandem mass spectrometry (LC-MS/MS) 2024-03-01 · Expand citations
- Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants. 2023-10-01 · Expand citations
- Pharmacokinetics and Pharmacodynamics of Oral Psilocybin Administration in Healthy Participants. 2023-04-01 · Expand citations
- A Single Method for 127 Recommended and Additional DUID Drugs in Blood and Urine by LC-MS-MS. 2022-07-14 · Expand citations
- Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects. 2022-05-01 · Expand citations
- Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects. 2022-04-01 · Expand citations
- Dose-response relationships of psilocybin-induced subjective experiences in humans. 2021-04-01 · Expand citations
- Development and validation of an LC-MS/MS method for the bioanalysis of psilocybin’s main metabolites, psilocin and 4-hydroxyindole-3-acetic acid, in human plasma 2021-02-01 · Expand citations
- Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels 2019-06-01 · Expand citations
- Biological Effects and Biodistribution of Bufotenine on Mice. 2018-01-01 · Expand citations
- Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults. 2017-12-01 · Expand citations
- Synthesis, hydrolysis and stability of psilocin glucuronide 2014-04-01 · Expand citations
- Determination of psilocin, bufotenine, LSD and its metabolites in serum, plasma and urine by SPE-LC-MS/MS 2013-05-01 · Expand citations
- A validated method for quantitation of psilocin in plasma by LC-MS/MS and study of stability 2012-11-01 · Expand citations
- Glucuronidation of Psilocin and 4-Hydroxyindole by the Human UDP-Glucuronosyltransferases 2010-03-01 · Expand citations
- Direct detection of serum psilocin glucuronide by LC/MS and LC/MS/MS: time-courses of total and free (unconjugated) psilocin concentrations in serum specimens of a “magic mushroom” user 2006-07-01 · Expand citations
- Investigation into the temporal stability of aqueous standard solutions of psilocin and psilocybin using high performance liquid chromatography 2006-04-01 · Expand citations
- Optimized glucuronide hydrolysis for the detection of psilocin in human urine samples 2003-11-01 · Expand citations
- Renal excretion profiles of psilocin following oral administration of psilocybin: a controlled study in man 2002-09-01 · Expand citations
- Detection of psilocin in body fluids 2000-09-01 · Expand citations
- Quantitation of psilocin in human plasma by high-performance liquid chromatography and electrochemical detection: comparison of liquid-liquid extraction with automated on-line solid-phase extraction 1998-05-01 · Expand citations
- Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man 1997-06-01 · Expand citations
- 10.1016/0024-3205(76)90441-0
- 10.1016/0165-1781(95)02747-k
- 10.1016/j.fsir.2023.100336
- 10.1016/j.talo.2022.100171
- 10.1080/00365510510013604
- 10.1080/02791072.1996.10472488
- 10.1177/0004563214554842
- 10.3390/ijms21239279
Cited by — these papers cite this paper (0)
No citing papers identified in the available metadata. This does not establish that none exist.